Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-11-01
2005-11-01
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S184000, C514S483000, C514S365000, C514S387000, C514S547000, C514S674000, C514S023000, C514S058000, C514S059000, C514S502000, C536S004100, C424S489000, C424S733000, C424S009362
Reexamination Certificate
active
06960571
ABSTRACT:
A method of treating Restless Leg Syndrome, includes administering to a subject an iron complex having an iron release rate greater than IDI. The iron release rate is determined at a concentration of at least 2,000 μg/dl.
REFERENCES:
patent: 4827945 (1989-05-01), Groman et al.
patent: 5248492 (1993-09-01), Groman et al.
patent: 5700832 (1997-12-01), Baik et al.
patent: 6611707 (2003-08-01), Prausnitz et al.
patent: WO 00/25821 (2000-05-01), None
patent: WO 01/74162 (2001-10-01), None
Earley et al. “Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome.” Neurology, 54, pp. 1698-1700, Apr. (2 of 2) 2000.
Allen et al., “MRI Measurement of Brain Iron in Patients with Restless Legs Syndrome,” Neurology, 2001, pp. 263-265, vol. 56.
Allen et al., “Augmentation of the Restless Legs Syndrome with Carbidopa/Levodopa,” Sleep, 1996, pp. 205-213, vol. 19.
Allen et al., “Restless Legs Syndrome: A Review of Clinical and Pathophysiologic Features,” J. Clin. Neurophysiol., 2001, pp. 128-147, vol. 18.
Allen et al., “Validation of the Johns Hopkins Restless Legs Severity Scale,” Sleep Medicine, 2001, pp. 239-242, vol. 2.
Bailie et al., “Restless Legs Syndrome—Focus on Dopaminergic Agents,” Med Facts, 2001, vol. 3, 1 page, obtained from http://www.nephrologypharmacy.com/downloads/Medfacts3-1.pdf.
Ben-Shachar et al., “Effect of Iron Chelators on Dopamine D2 Receptors,” J. Neurochem., 1985, pp. 999-1005, vol. 45.
Bonnet et al., “ASDA Report, Atlas and Scoring Rules,” Sleep, 1993, pp. 748-759, vol. 16.
Breuer et al., “A Fluorescence-Based One-Step Assay for Serum Non-Transferrin-Bound Iron,” Anal. Biochem., 2001, pp. 194-202, vol. 299.
Chesson et al., “Practice Parameters for the Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder, An American Academy of Sleep Medicine Report, Standards of Practice Committee of the American Academy of Sleep Medicine,” Sleep, 1999, pp. 961-968, vol. 22.
Conrad et al., “Iron Absorption and Transport,” Am. J. Med. Sci., 1999, pp. 213-229, vol. 318.
Danielson et al., “Pharmacokinetics of Iron(III_-Hydroxide Sucrose Complex After a Single Intravenous Dose in Healthy Volunteers,” Arzneimittelforschung, 1996, pp. 615-621, vol. 46.
Davis et al., “A Randomized, Double-Blind Placebo-Controlled Trial of Iron in Restless Legs Syndrome,” European Neurology, 2000, pp. 70-75, vol. 43.
Earley et al., “Pergolide and Carbidopa/Levodopa Treatment of the Restless Legs Syndrome and Periodic Leg Movements in Sleep in a Consecutive Series of Patients,” Sleep, 1996, pp. 801-810, vol. 19.
Earley et al., “Abnormalities in CFS Concentrations of Ferritin and Transferrin in Restless Legs Syndrome,” Neurology, 2000, pp. 1698-1700, vol. 54.
Earley et al., “Randomized, Double-Blind, Placebo-Controlled Trial of Pergolide in Restless Legs Syndrome,” Neurology, 1998, pp. 1599-1602, vol. 51.
Ekbom, “Restless Legs Syndrome,” Neurology, 1960, pp. 868-873, vol. 10.
Ekbom, “Restless Legs Syndrome,” Focus on Dopaminergic Agents, Med Facts, 2001, pp. 868-873, vol. 3.
Erikson et al., “Iron Deficiency Alters Dopamine Transporter Functioning in Rat Striatum,” J. Nutr., 2000, pp. 2831-2837, vol. 130.
Esposito et al., “Labile Iron in Parenteral Iron Formulations and its Potential for Generating Plasma Nontransferrin-Bound Iron in Dialysis Patients,” Eur. J. Clin. Invest., 2002, pp. 42-49, vol. 32.
Fishbane et al., “The Safety of Intravenous Iron Dextran in Hemodialysis Patients,” Am. J. Kidney Dis., 1996, pp. 529-534, vol. 28.
Geisser et al., “Structure/Histotoxicity Relationship of Parenteral Iron Preparations,” Arzneimittelforschung, 1992, pp. 1439-1452, vol. 42.
Gelman et al., “MR Imaging of Human Brain at 3.0 T: Preliminary Report on Transverse Relaxation Rates and Relation to Estimated Iron Content,” Radiology, 1999, pp. 759-767, vol. 210.
Gorny et al., “Evaluation of the PAM-RL System for the Detection of Periodic Leg Movements During Sleep in the Lab and Home Environments,” Sleep, 1986, p. 183, vol. 21.
Hamstra et al., “Intravenous Iron Dextran in Clinical Medicine,” JAMA, 1980, pp. 1726-1731, vol. 243.
Hening et al., “Dyskinesias While Awake and Periodic Movements in Sleep in Restless Legs Syndrome: Treatment with Opoids,” Neurology, 1986, pp. 1361-1366, vol. 36.
Hening et al., “The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder, An American Academy of Sleep Medicine Review,” Sleep, 1999, pp. 970-999, vol. 22.
Jacobs et al., “Colorimetry and Constant-Potential Coulometry Determinations of Transferrin-Bound Iron, Total Iron-Binding Capacity, and Total Iron in Serum Containing Iron-Dextran, with Use of Sodium Dithionite and Alumina Columns,” Clin. Chem., 1990, pp. 1803-1807, vol. 36.
Montplaisir et al., “Restless Legs Syndrome and periodic Movements in Sleep: Physiopathology and Treatment with L-dopa,” Clin. Neuropharmacol., 1986, pp. 456-463, vol. 9.
Montplaisir et al., “Immobilization Tests and Periodic Leg Movements in Sleep for the Diagnosis of Restless Leg Syndrome,” Mov. Disord., 1998, pp. 324-329, vol. 13.
Montplaisir et al, “Restless Legs Syndrome and Periodic Leg Movements in Sleep: The Primary Role of Dopaminergic Mechanism,” Eur. Neurol., 1991, pp. 41-43, vol. 31.
Nelson et al., “In vivo Dopamine Metabolism is Altered in Iron-Deficient Anemic Rats,” J. Nutr., 1997, pp. 2282-2288, vol. 127.
Nordlander, “Therapy in Restless Legs,” Acta Medica Scandinavica, 1953, pp. 453-457, vol. 145.
O'Keeffe et al., “Iron Status and Restless Legs Syndrome in the Elderly,” Age Ageing, 1994, pp. 200-203, vol. 23 (and abstract only from http://ageing.oupjournals.org/cgi/content/abstract/23/200).
Pelletier et al., “Sensory and Motor Components of the Restless Legs Syndrome,” Neurology, 1992, pp. 1663-1666, vol. 42.
Pollmacher et al., “Periodic Leg Movements (PLM): Their Relationship to Sleep Stages,” Sleep, 1993, pp. 572-577, vol. 16.
Silber et al., “Pergolide in the Management of Restless Legs Syndrome: An Extended Study,” Sleep, 1997, pp. 878-882, vol. 20.
Simon, “Anemia,” http://www.healthandage.com/html/well_connected/pdf/doc57.pdf, 17 pages, 2003.
Staedt et al., “Nocturnal Myoclonus Syndrome (Periodic Movements in Sleep) Related to Central Dopamine D2-Receptor Alteration,” Eur. Arch. Psychiatry Clin. Neurosci., 1995, pp. 8-10, vol. 245.
Sun et al., “Iron and the Restless Legs Syndrome,” Sleep, 1998, pp. 381-387, vol. 21.
Turjanski et al., “Striatal Dopaminergic Function in Restless Legs Syndrome: 18F-dopa and 11C-raclopride PET Studies,” Neurology, 1999, pp. 932-937, vol. 52.
Ward et al., “Brain Iron in the Ferrocene-Loaded Rat: Its Chelation and Influence on Dopamine Metabolism,” Biochem. Pharmacol., 1995, pp. 1821-1826, vol. 49.
RLS-QLI Restless Legs Syndrome-Quality of Life Instrument; RLS-QLI © RLS Foundation, May 1, 2002.
SF-12 Health Survey, Protocol PPXAPD-0072-138, Final Jan. 22, 2002.
Helenek Mary Jane
Lange Ralf A.
Oldham Fred B.
Tokars Marc L.
Khare Devesh
Luitpold Pharmaceuticals, Inc.
Sonnenschein Nath & Rosenthal LLP
Wilson James O.
LandOfFree
Methods and compositions for administration of iron for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for administration of iron for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for administration of iron for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3458573